CAOV3 Xenograft Model Overview
The CAOV3 xenograft model is derived from a human ovarian carcinoma cell line, established from a patient with metastatic serous ovarian cancer. Serous ovarian carcinoma is the most common and aggressive subtype of ovarian cancer, and its metastatic potential often leads to late-stage diagnosis and poor prognosis. The CAOV3 xenograft model is widely used in preclinical research to investigate the molecular mechanisms driving ovarian cancer progression, evaluate novel therapeutic strategies, and study the mechanisms of drug resistance. Given its clinical relevance, particularly its response to chemotherapy and resistance to certain drugs, the CAOV3 model is valuable for testing both traditional and targeted therapies aimed at improving patient outcomes.
Request a Custom Quote for CAOV3 Xenograft ModelBiological and Molecular Characteristics
CAOV3 cells are characterized by their epithelial origin and express common ovarian cancer markers such as cytokeratins, epithelial membrane antigen (EMA), and the ovarian cancer-associated antigen CA-125. These cells are also known to express the estrogen receptor (ER), which makes them useful for testing hormone-based therapies. CAOV3 cells harbor mutations in critical tumor suppressor genes like TP53, contributing to their high proliferative capacity, resistance to apoptosis, and aggressive tumor behavior. The model is sensitive to platinum-based chemotherapies, including cisplatin, but can develop resistance over time, making it an ideal platform for studying the development of drug resistance and for evaluating combination therapies. Additionally, CAOV3 cells show dysregulation in the PI3K/AKT and MAPK signaling pathways, which contribute to their survival and proliferation. These pathways are often targeted in the development of novel therapeutics for ovarian cancer.
| Marker | Expression Level | Function |
|---|---|---|
| Cytokeratin | High | Epithelial cell marker |
| EMA | High | Epithelial membrane antigen |
| CA-125 | High | Ovarian cancer-associated antigen |
| Estrogen Receptor | Positive | Hormone receptor involved in growth |
| PI3K/AKT pathway | Dysregulated | Promotes cell survival and proliferation |
In Vivo Model Development and Tumorigenicity
The CAOV3 xenograft model is typically established by subcutaneously implanting CAOV3 cells into immunocompromised mice, such as NOD/SCID or NSG mice. Upon implantation, the CAOV3 cells form tumors that resemble human ovarian carcinoma in terms of morphology and metastatic potential. The tumors exhibit high cellularity, frequent necrosis, and significant vascularization, indicative of the rapid growth and angiogenesis of the tumor. The model is particularly useful for studying tumor progression, metastasis, and the effects of chemotherapy. Given that CAOV3 xenografts can develop resistance to cisplatin, they are an excellent model for investigating the molecular mechanisms underlying chemotherapy resistance and for evaluating new drug candidates that aim to overcome such resistance.
In addition to subcutaneous implantation, orthotopic models can be established by implanting CAOV3 cells into the ovarian bursa or peritoneal cavity, which more closely mimics the natural growth and dissemination of ovarian cancer. This orthotopic implantation allows for the study of peritoneal metastasis, one of the hallmark features of advanced ovarian cancer, and provides a clinically relevant setting for evaluating the efficacy of treatments targeting peritoneal spread.
Request a Custom Quote for CAOV3 Xenograft ModelHistopathology and Immunohistochemical Profile
Histopathological examination of CAOV3 xenografts reveals tumors with characteristic features of serous ovarian carcinoma, including large, pleomorphic tumor cells and regions of necrosis. The tumors often show a mixture of solid and cystic growth patterns, which are typical of ovarian carcinoma. Immunohistochemical staining reveals high expression of epithelial markers, such as cytokeratin and EMA, confirming the epithelial origin of the tumor. Additionally, CAOV3 xenografts show elevated levels of CA-125, which is a biomarker commonly elevated in ovarian cancer patients. The tumors also express estrogen receptors, making them relevant for testing hormone-based therapies. Staining for markers of angiogenesis, such as CD31, reveals significant vascularization within the tumors, indicative of active tumor growth. Furthermore, the tumors show dysregulated PI3K/AKT signaling, with high levels of phosphorylated AKT, which contributes to the survival and proliferation of tumor cells.
Preclinical Applications and Drug Response
The CAOV3 xenograft model is widely used to evaluate the efficacy of various therapeutic agents for ovarian cancer. Given its sensitivity to platinum-based chemotherapy, such as cisplatin and carboplatin, the CAOV3 model is particularly valuable for testing combination therapies that aim to overcome chemotherapy resistance. The model is also useful for investigating targeted therapies, particularly those targeting the PI3K/AKT and MAPK signaling pathways, which are often dysregulated in ovarian cancer.
In addition to chemotherapy and targeted therapies, the CAOV3 xenograft model is frequently employed to evaluate the effectiveness of immunotherapies, including immune checkpoint inhibitors and monoclonal antibodies targeting ovarian cancer-specific antigens such as CA-125. The model’s ability to replicate key features of ovarian carcinoma, including its resistance to chemotherapy and propensity for metastasis, makes it an ideal preclinical platform for developing and testing new therapeutic agents aimed at improving the survival and quality of life for ovarian cancer patients.
Request This Model
To request the CAOV3 xenograft model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for CAOV3 Xenograft Model